Guest: Deepa Rangachari, MD <br>


  <p>With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.</p>

Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

On the Forefront of NSCLC Treatment: Targeting RET Mutations

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 Sponsored by

Medicine

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;Sponsored by

Share On the Forefront of NSCLC Treatment: Targeting RET Mutations

Sign up to save your podcasts

On the Forefront of NSCLC Treatment: Targeting RET Mutations

On the Forefront of NSCLC Treatment: Targeting RET Mutations